<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00492063</url>
  </required_header>
  <id_info>
    <org_study_id>V58P4</org_study_id>
    <nct_id>NCT00492063</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of a Cell Culture-derived Influenza Vaccine in Healthy Adults and Elderly</brief_title>
  <official_title>A Phase III, Observer-Blind, Randomized, Multi-Center Study to Evaluate Safety, Tolerability and Immunogenicity of a Single Intramuscular Dose of a Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture and of a Trivalent Subunit Influenza Vaccine Produced in Embryonated Hen Eggs, in Healthy Adult and Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study aims to evaluate the safety and immunogenicity of the new influenza subunit
      vaccine produced in Madin Darby Canine Kidney (MDCK) cells in healthy adult and elderly
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">May 2005</completion_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentages Of Subjects Who Achieved HI Titer ≥40 After One Vaccination of Cell Culture-derived (cTIV) or Egg-derived (TIV) Influenza Subunit Vaccines</measure>
    <time_frame>Before vaccination (day 1) and three weeks after vaccination (day 22)</time_frame>
    <description>Immunogenicity was measured as the percentage of adults (≥18 to ≤60 years) and elderly (≥61 years) achieving HI titers ≥40 at baseline (day 1) and three weeks (day 22) after one vaccination of cTIV or TIV vaccine for each of three vaccine strains, evaluated using the hemagglutination inhibition (HI) egg-derived antigen assay.
In compliance with the requirements of the EMEA recommendations (CPMP/BWP/2490/00, CPMP/BWP/214/96), this criterion is met if the percentage of subjects achieving HI titers ≥40 is &gt;70% in the ≥18 to ≤60 years of age group or &gt;60% in the ≥61 years of age group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages Of Subjects Who Achieved Seroconversion Or Significant Increase In HI Titer After One Vaccination of cTIV or TIV</measure>
    <time_frame>Three weeks after vaccination (day 22)</time_frame>
    <description>Seroconversion or significant in HI titer is defined as the percentage of subjects with a prevaccination HI titer &lt;10 (negative) to a postvaccination titer ≥40; or in subjects with prevaccination HI titer ≥10, at least a 4-fold increase in postvaccination HI titer. In compliance with the requirements of the EMEA recommendations (CPMP/BWP/2490/00, CPMP/BWP/214/96), the criterion is met if the percentage of subjects achieving seroconversion/significant increase is &gt;40% in the ≥18 to ≤60 years of age group or &gt;30% in the ≥61 years of age group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Ratio of Subjects After One Vaccination of cTIV or TIV</measure>
    <time_frame>Three weeks after vaccination (day 22)</time_frame>
    <description>Immunogenicity was measured as the geometric mean ratio (GMR), calculated as the ratio of postvaccination to prevaccination HI Geometric Mean Titers (GMTs), three weeks after (day 22) one vaccination of cTIV or TIV. In compliance with the requirements of the EMEA recommendations (CPMP/BWP/2490/00, CPMP/BWP/214/96), this criterion is met if the GMR (day 22/day 1) in HI antibody titer is &gt;2.5 in the ≥18 to ≤60 years of age group or &gt;2.0 in the ≥61 years of age group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Reported Solicited Local and Systemic Reactions up to 7 Days After Vaccination</measure>
    <time_frame>Up to 7 days postvaccination</time_frame>
    <description>The solicited local and systemic reactions were collected from day 1 up to and including day 7 after vaccination for both the vaccine groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2654</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Cell culture-derived influenza vaccine (cTIV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Egg-derived influenza virus vaccine (TIV)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cell culture-derived trivalent subunit influenza vaccine (cTIV)</intervention_name>
    <description>One vaccination (0.5 mL) of cell culture-derived influenza vaccine (cTIV) was administered in the deltoid muscle</description>
    <arm_group_label>Cell culture-derived influenza vaccine (cTIV)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Egg-derived trivalent subunit influenza vaccine (TIV)</intervention_name>
    <description>One vaccination (0.5 mL) of egg-derived influenza virus vaccine (TIV) was administered in the deltoid muscle</description>
    <arm_group_label>Egg-derived influenza virus vaccine (TIV)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 to 60 years of age (first age group) OR over 60 years of age (second age group)

          2. mentally competent to understand the nature, the scope and the consequences of the
             study

          3. able and willing to give written informed consent prior to study entry

          4. available for all the visits scheduled in the study

          5. residence in the study area

          6. in good health as determined by:

               1. medical history,

               2. physical examination,

               3. clinical judgment of the investigator.

        Exclusion Criteria:

          1. unable or unwilling to give written informed consent to participate in the study

          2. suffering from an acute infectious disease

          3. any serious disease such as:

               1. cancer (except for benign or localized skin cancer and non metastatic prostate
                  cancer not currently treated with chemotherapy),_

               2. autoimmune disease (including rheumatoid arthritis),

               3. advanced arteriosclerotic disease or complicated diabetes mellitus,

               4. chronic obstructive pulmonary disease (COPD) requiring oxygen therapy,

               5. acute or progressive hepatic disease,

               6. acute or progressive renal disease,

               7. congestive heart failure

          4. surgery planned during the study period

          5. bleeding diathesis

          6. history of hypersensitivity to any component of the study medication or chemically
             related substances, such as allergy to eggs or egg products

          7. known or suspected impairment/alteration of immune function resulting from:

               1. receipt of immunosuppressive therapy (any cortical steroid or cancer
                  chemotherapy),

               2. receipt of immunostimulants,

               3. receipt of parenteral immunoglobulin preparation, blood products, and/or plasma
                  derivatives within the past 3 months and for the full length of the study,

               4. high risk for developing an immunocompromising disease within the past 6 months

          8. history of drug or alcohol abuse

          9. laboratory confirmed influenza disease in the past 6 months

         10. received influenza vaccine within the past 6 months

         11. received another vaccine or any investigational agent within the past 60 days, or
             planned vaccination within 3 weeks following the study vaccination

         12. any acute respiratory disease or infections requiring systemic antibiotic or antiviral
             therapy (chronic antibiotic therapy for urinary tract prophylaxis was acceptable) or
             experienced fever ≥ 38°C within the past 3 days

         13. pregnant women or women who refused to use a reliable contraceptive method throughout
             the study (180 days)

         14. any condition which, in the opinion of the investigator, might have interfered with
             the evaluation of the study objectives.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wojewódzki Szpital Dzieciecy</name>
      <address>
        <city>ul. Langiewicza 2</city>
        <state>Kielce</state>
        <zip>25-381</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>N ZOZ Jagiellonskie, Centrum Medyczne Sp. z o.o.</name>
      <address>
        <city>os. Jagiellonskie 1</city>
        <state>Kraków</state>
        <zip>31-832</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praktyka Grupowa Lekarzy POZ &quot;Familia&quot;</name>
      <address>
        <city>Pl. Sikorskiego 6a</city>
        <state>Kraków</state>
        <zip>31-115</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Jana Pawła II</name>
      <address>
        <city>ul. Pradnicka 80</city>
        <state>Kraków</state>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Farmakologii Klinicznej</name>
      <address>
        <city>Krakow</city>
        <zip>30-969</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <results_reference>
    <citation>Szymczakiewicz-Multanowska A, Groth N, Bugarini R, Lattanzi M, Casula D, Hilbert A, Tsai T, Podda A. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. J Infect Dis. 2009 Sep 15;200(6):841-8. doi: 10.1086/605505. Erratum in: J Infect Dis. 2009 Dec 1;200(11):1801-2.</citation>
    <PMID>19673651</PMID>
  </results_reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2007</study_first_submitted>
  <study_first_submitted_qc>June 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2007</study_first_posted>
  <results_first_submitted>December 11, 2012</results_first_submitted>
  <results_first_submitted_qc>January 18, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 21, 2013</results_first_posted>
  <last_update_submitted>December 3, 2015</last_update_submitted>
  <last_update_submitted_qc>December 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety</keyword>
  <keyword>immunogenicity</keyword>
  <keyword>non-inferiority</keyword>
  <keyword>MDCK</keyword>
  <keyword>cell culture-derived</keyword>
  <keyword>subunit influenza vaccine</keyword>
  <keyword>influenza prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled at 5 sites in Poland.</recruitment_details>
      <pre_assignment_details>All enrolled subjects were included in the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>cTIV (Adults)</title>
          <description>Subjects ≥18 to ≤60 years of age who received one vaccination of cell culture-derived influenza virus vaccine (cTIV)</description>
        </group>
        <group group_id="P2">
          <title>TIV (Adults)</title>
          <description>Subjects ≥18 to ≤60 years of age who received one vaccination of egg-derived influenza virus vaccine (TIV)</description>
        </group>
        <group group_id="P3">
          <title>cTIV (Elderly)</title>
          <description>Subjects ≥61 years of age who received one vaccination of cell culture-derived influenza virus vaccine (cTIV)</description>
        </group>
        <group group_id="P4">
          <title>TIV (Elderly)</title>
          <description>Subjects ≥61 years of age who received one vaccination of egg-derived influenza virus vaccine (TIV)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="652"/>
                <participants group_id="P2" count="648"/>
                <participants group_id="P3" count="678"/>
                <participants group_id="P4" count="676"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="642"/>
                <participants group_id="P2" count="634"/>
                <participants group_id="P3" count="667"/>
                <participants group_id="P4" count="666"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>cTIV (Adults)</title>
          <description>Subjects ≥18 to ≤60 years of age who received one vaccination of cell culture-derived influenza virus vaccine (cTIV)</description>
        </group>
        <group group_id="B2">
          <title>TIV (Adults)</title>
          <description>Subjects ≥18 to ≤60 years of age who received one vaccination of egg-derived influenza virus vaccine (TIV)</description>
        </group>
        <group group_id="B3">
          <title>cTIV (Elderly)</title>
          <description>Subjects ≥61 years of age who received one vaccination of cell culture-derived influenza virus vaccine (cTIV)</description>
        </group>
        <group group_id="B4">
          <title>TIV (Elderly)</title>
          <description>Subjects ≥61 years of age who received one vaccination of egg-derived influenza virus vaccine (TIV)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="652"/>
            <count group_id="B2" value="648"/>
            <count group_id="B3" value="678"/>
            <count group_id="B4" value="676"/>
            <count group_id="B5" value="2654"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.7" spread="12.7"/>
                    <measurement group_id="B2" value="38.3" spread="13.3"/>
                    <measurement group_id="B3" value="69.1" spread="5.7"/>
                    <measurement group_id="B4" value="68.8" spread="5.6"/>
                    <measurement group_id="B5" value="54.0" spread="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="376"/>
                    <measurement group_id="B2" value="371"/>
                    <measurement group_id="B3" value="389"/>
                    <measurement group_id="B4" value="375"/>
                    <measurement group_id="B5" value="1511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="276"/>
                    <measurement group_id="B2" value="277"/>
                    <measurement group_id="B3" value="289"/>
                    <measurement group_id="B4" value="301"/>
                    <measurement group_id="B5" value="1143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentages Of Subjects Who Achieved HI Titer ≥40 After One Vaccination of Cell Culture-derived (cTIV) or Egg-derived (TIV) Influenza Subunit Vaccines</title>
        <description>Immunogenicity was measured as the percentage of adults (≥18 to ≤60 years) and elderly (≥61 years) achieving HI titers ≥40 at baseline (day 1) and three weeks (day 22) after one vaccination of cTIV or TIV vaccine for each of three vaccine strains, evaluated using the hemagglutination inhibition (HI) egg-derived antigen assay.
In compliance with the requirements of the EMEA recommendations (CPMP/BWP/2490/00, CPMP/BWP/214/96), this criterion is met if the percentage of subjects achieving HI titers ≥40 is &gt;70% in the ≥18 to ≤60 years of age group or &gt;60% in the ≥61 years of age group.</description>
        <time_frame>Before vaccination (day 1) and three weeks after vaccination (day 22)</time_frame>
        <population>Analysis was done on the per-protocol (PP) set, i.e. the subjects who received the vaccination correctly; provided evaluable data before and after vaccination; and with no major protocol violations, as defined before unblinding.</population>
        <group_list>
          <group group_id="O1">
            <title>cTIV (Adults)</title>
            <description>Subjects ≥18 to ≤60 years of age who received one vaccination of cell culture-derived influenza virus vaccine (cTIV)</description>
          </group>
          <group group_id="O2">
            <title>TIV (Adults)</title>
            <description>Subjects ≥18 to ≤60 years of age who received one vaccination of egg-derived influenza virus vaccine (TIV)</description>
          </group>
          <group group_id="O3">
            <title>cTIV (Elderly)</title>
            <description>Subjects ≥61 years of age who received one vaccination of cell culture-derived influenza virus vaccine (cTIV)</description>
          </group>
          <group group_id="O4">
            <title>TIV (Elderly)</title>
            <description>Subjects ≥61 years of age who received one vaccination of egg-derived influenza virus vaccine (TIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages Of Subjects Who Achieved HI Titer ≥40 After One Vaccination of Cell Culture-derived (cTIV) or Egg-derived (TIV) Influenza Subunit Vaccines</title>
          <description>Immunogenicity was measured as the percentage of adults (≥18 to ≤60 years) and elderly (≥61 years) achieving HI titers ≥40 at baseline (day 1) and three weeks (day 22) after one vaccination of cTIV or TIV vaccine for each of three vaccine strains, evaluated using the hemagglutination inhibition (HI) egg-derived antigen assay.
In compliance with the requirements of the EMEA recommendations (CPMP/BWP/2490/00, CPMP/BWP/214/96), this criterion is met if the percentage of subjects achieving HI titers ≥40 is &gt;70% in the ≥18 to ≤60 years of age group or &gt;60% in the ≥61 years of age group.</description>
          <population>Analysis was done on the per-protocol (PP) set, i.e. the subjects who received the vaccination correctly; provided evaluable data before and after vaccination; and with no major protocol violations, as defined before unblinding.</population>
          <units>Percentages</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="650"/>
                <count group_id="O2" value="644"/>
                <count group_id="O3" value="672"/>
                <count group_id="O4" value="674"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="26" upper_limit="33"/>
                    <measurement group_id="O2" value="33" lower_limit="29" upper_limit="36"/>
                    <measurement group_id="O3" value="30" lower_limit="27" upper_limit="34"/>
                    <measurement group_id="O4" value="31" lower_limit="27" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="89" upper_limit="94"/>
                    <measurement group_id="O2" value="92" lower_limit="89" upper_limit="94"/>
                    <measurement group_id="O3" value="85" lower_limit="82" upper_limit="87"/>
                    <measurement group_id="O4" value="85" lower_limit="82" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="61" upper_limit="69"/>
                    <measurement group_id="O2" value="63" lower_limit="60" upper_limit="67"/>
                    <measurement group_id="O3" value="66" lower_limit="63" upper_limit="70"/>
                    <measurement group_id="O4" value="59" lower_limit="56" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="99" lower_limit="98" upper_limit="99"/>
                    <measurement group_id="O3" value="97" lower_limit="96" upper_limit="98"/>
                    <measurement group_id="O4" value="98" lower_limit="97" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="13" upper_limit="19"/>
                    <measurement group_id="O2" value="18" lower_limit="15" upper_limit="22"/>
                    <measurement group_id="O3" value="23" lower_limit="20" upper_limit="26"/>
                    <measurement group_id="O4" value="20" lower_limit="17" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="88" upper_limit="93"/>
                    <measurement group_id="O2" value="91" lower_limit="88" upper_limit="93"/>
                    <measurement group_id="O3" value="90" lower_limit="88" upper_limit="92"/>
                    <measurement group_id="O4" value="89" lower_limit="87" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority testing in immune response (HI titer ≥40) of cTIV to that of TIV vaccine for strain A/H1N1 after one vaccination in adults.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The percentage of subjects with HI titer ≥40 in the cTIV group is &gt;10% lower than in the TIV group (i.e., the percentage of subjects with HI titer ≥40 in the cTIV group is non-inferior to that of TIV group if, for strain A/H1N1, the lower limit of the 95% CI of the difference in the percentages is greater than -10%)</non_inferiority_desc>
            <param_type>Group difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority testing in immune response (HI titer ≥40) of cTIV to that of TIV vaccine for strain A/H3N2 after one vaccination in adults.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The percentage of subjects with HI titer ≥40 in the cTIV group is &gt;10% lower than in the TIV group (i.e., the percentage of subjects with HI titer ≥40 in the cTIV group is non-inferior to that of TIV group if, for strain A/H3N2, the lower limit of the 95% CI of the difference in the percentages is greater than -10%)</non_inferiority_desc>
            <param_type>Group difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority testing in immune response (HI titer ≥40) of cTIV to that of TIV vaccine for strain B after one vaccination in adults.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The percentage of subjects with HI titer ≥40 in the cTIV group is &gt;10% lower than in the TIV group (i.e., the percentage of subjects with HI titer ≥40 in the cTIV group is non-inferior to that of TIV group if, for strain B, the lower limit of the 95% CI of the difference in the percentages is greater than -10%)</non_inferiority_desc>
            <param_type>Group difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority testing in immune response (HI titer ≥40) of cTIV to that of TIV vaccine for strain A/H1N1 after one vaccination in the elderly population.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The percentage of subjects with HI titer ≥40 in the cTIV group is &gt;10% lower than in the TIV group (i.e., the percentage of subjects with HI titer ≥40 in the cTIV group is non-inferior to that of TIV group if, for strain A/H1N1, the lower limit of the 95% CI of the difference in the percentages is greater than -10%)</non_inferiority_desc>
            <param_type>Group difference</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority testing in immune response (HI titer ≥40) of cTIV to that of TIV vaccine for strain A/H3N2 after one vaccination in the elderly population.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The percentage of subjects with HI titer ≥40 in the cTIV group is &gt;10% lower than in the TIV group (i.e., the percentage of subjects with HI titer ≥40 in the cTIV group is non-inferior to that of TIV group if, for strain A/H3N2, the lower limit of the 95% CI of the difference in the percentages is greater than -10%)</non_inferiority_desc>
            <param_type>Group difference</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2</ci_lower_limit>
            <ci_upper_limit>1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority testing in immune response (HI titer ≥40) of cTIV to that of TIV vaccine for strain B after one vaccination in the elderly population.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The percentage of subjects with HI titer ≥40 in the cTIV group is &gt;10% lower than in the TIV group (i.e., the percentage of subjects with HI titer ≥40 in the cTIV group is non-inferior to that of TIV group if, for strain B, the lower limit of the 95% CI of the difference in the percentages is greater than -10%)</non_inferiority_desc>
            <param_type>Group difference</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2</ci_lower_limit>
            <ci_upper_limit>4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentages Of Subjects Who Achieved Seroconversion Or Significant Increase In HI Titer After One Vaccination of cTIV or TIV</title>
        <description>Seroconversion or significant in HI titer is defined as the percentage of subjects with a prevaccination HI titer &lt;10 (negative) to a postvaccination titer ≥40; or in subjects with prevaccination HI titer ≥10, at least a 4-fold increase in postvaccination HI titer. In compliance with the requirements of the EMEA recommendations (CPMP/BWP/2490/00, CPMP/BWP/214/96), the criterion is met if the percentage of subjects achieving seroconversion/significant increase is &gt;40% in the ≥18 to ≤60 years of age group or &gt;30% in the ≥61 years of age group.</description>
        <time_frame>Three weeks after vaccination (day 22)</time_frame>
        <population>Analysis was performed on the PP set.</population>
        <group_list>
          <group group_id="O1">
            <title>cTIV (Adults)</title>
            <description>Subjects ≥18 to ≤60 years of age who received one vaccination of cell culture-derived influenza virus vaccine (cTIV)</description>
          </group>
          <group group_id="O2">
            <title>TIV (Adults)</title>
            <description>Subjects ≥18 to ≤60 years of age who received one vaccination of egg-derived influenza virus vaccine (TIV)</description>
          </group>
          <group group_id="O3">
            <title>cTIV (Elderly)</title>
            <description>Subjects ≥61 years of age who received one vaccination of cell culture-derived influenza virus vaccine (cTIV)</description>
          </group>
          <group group_id="O4">
            <title>TIV (Elderly)</title>
            <description>Subjects ≥61 years of age who received one vaccination of egg-derived influenza virus vaccine (TIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages Of Subjects Who Achieved Seroconversion Or Significant Increase In HI Titer After One Vaccination of cTIV or TIV</title>
          <description>Seroconversion or significant in HI titer is defined as the percentage of subjects with a prevaccination HI titer &lt;10 (negative) to a postvaccination titer ≥40; or in subjects with prevaccination HI titer ≥10, at least a 4-fold increase in postvaccination HI titer. In compliance with the requirements of the EMEA recommendations (CPMP/BWP/2490/00, CPMP/BWP/214/96), the criterion is met if the percentage of subjects achieving seroconversion/significant increase is &gt;40% in the ≥18 to ≤60 years of age group or &gt;30% in the ≥61 years of age group.</description>
          <population>Analysis was performed on the PP set.</population>
          <units>Percentages</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="650"/>
                <count group_id="O2" value="644"/>
                <count group_id="O3" value="672"/>
                <count group_id="O4" value="674"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" lower_limit="65" upper_limit="73"/>
                    <measurement group_id="O2" value="67" lower_limit="63" upper_limit="71"/>
                    <measurement group_id="O3" value="55" lower_limit="51" upper_limit="59"/>
                    <measurement group_id="O4" value="55" lower_limit="51" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63" lower_limit="59" upper_limit="67"/>
                    <measurement group_id="O2" value="64" lower_limit="60" upper_limit="68"/>
                    <measurement group_id="O3" value="68" lower_limit="65" upper_limit="72"/>
                    <measurement group_id="O4" value="65" lower_limit="61" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="82" upper_limit="87"/>
                    <measurement group_id="O2" value="81" lower_limit="78" upper_limit="84"/>
                    <measurement group_id="O3" value="80" lower_limit="77" upper_limit="83"/>
                    <measurement group_id="O4" value="73" lower_limit="70" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority testing in immune response (seroconversion or significant increase in HI titer) after one vaccination of cTIV to that of TIV vaccine for strain A/H1N1 in adults.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The percentage of subjects with seroconversion or significant increase in HI titer in the cTIV group is &gt;10% lower than in the TIV group (i.e., the percentage of subjects with seroconversion or significant in HI titer of cTIV group is non-inferior to that of the TIV group if, for strain A/H1N1, the lower limit of the 95% CI of the difference in the percentages is greater than -10%).</non_inferiority_desc>
            <param_type>Group difference</param_type>
            <param_value>2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3</ci_lower_limit>
            <ci_upper_limit>7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority testing in immune response (seroconversion or significant increase in HI titer) after one vaccination of cTIV to that of TIV vaccine for strain A/H3N2 in adults.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The percentage of subjects with seroconversion or significant increase in HI titer in the cTIV group is &gt;10% lower than in the TIV group (i.e., the percentage of subjects with seroconversion or significant in HI titer of cTIV group is non-inferior to that of the TIV group if, for strain A/H3N2, the lower limit of the 95% CI of the difference in the percentages is greater than -10%).</non_inferiority_desc>
            <param_type>Group difference</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6</ci_lower_limit>
            <ci_upper_limit>4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority testing in immune response (seroconversion or significant increase in HI titer) after one vaccination of cTIV to that of TIV vaccine for strain B in adults.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The percentage of subjects with seroconversion or significant increase in HI titer in the cTIV group is &gt;10% lower than in the TIV group (i.e., the percentage of subjects with seroconversion or significant in HI titer of cTIV group is non-inferior to that of the TIV group if, for strain B, the lower limit of the 95% CI of the difference in the percentages is greater than -10%).</non_inferiority_desc>
            <param_type>Group difference</param_type>
            <param_value>4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority testing in immune response (seroconversion or significant increase in HI titer) after one vaccination of cTIV to that of TIV vaccine for strain A/H1N1 in the elderly population.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The percentage of subjects with seroconversion or significant increase in HI titer in the cTIV group is &gt;10% lower than in the TIV group (i.e., the percentage of subjects with seroconversion or significant in HI titer of cTIV group is non-inferior to that of the TIV group if, for strain A/H1N1, the lower limit of the 95% CI of the difference in the percentages is greater than -10%).</non_inferiority_desc>
            <param_type>Group difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6</ci_lower_limit>
            <ci_upper_limit>5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority testing in immune response (seroconversion or significant increase in HI titer) after one vaccination of cTIV to that of TIV vaccine for strain A/H3N2 in the elderly population.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The percentage of subjects with seroconversion or significant increase in HI titer in the cTIV group is &gt;10% lower than in the TIV group (i.e., the percentage of subjects with seroconversion or significant in HI titer of cTIV group is non-inferior to that of the TIV group if, for strain A/H3N2, the lower limit of the 95% CI of the difference in the percentages is greater than -10%).</non_inferiority_desc>
            <param_type>Group difference</param_type>
            <param_value>3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2</ci_lower_limit>
            <ci_upper_limit>8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority testing in immune response (seroconversion or significant increase in HI titer) after one vaccination of cTIV to that of TIV vaccine for strain B in the elderly population.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The percentage of subjects with seroconversion or significant increase in HI titer in the cTIV group is &gt;10% lower than in the TIV group (i.e., the percentage of subjects with seroconversion or significant in HI titer of cTIV group is non-inferior to that of the TIV group if, for strain B, the lower limit of the 95% CI of the difference in the percentages is greater than -10%).</non_inferiority_desc>
            <param_type>Group difference</param_type>
            <param_value>6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2</ci_lower_limit>
            <ci_upper_limit>11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Ratio of Subjects After One Vaccination of cTIV or TIV</title>
        <description>Immunogenicity was measured as the geometric mean ratio (GMR), calculated as the ratio of postvaccination to prevaccination HI Geometric Mean Titers (GMTs), three weeks after (day 22) one vaccination of cTIV or TIV. In compliance with the requirements of the EMEA recommendations (CPMP/BWP/2490/00, CPMP/BWP/214/96), this criterion is met if the GMR (day 22/day 1) in HI antibody titer is &gt;2.5 in the ≥18 to ≤60 years of age group or &gt;2.0 in the ≥61 years of age group.</description>
        <time_frame>Three weeks after vaccination (day 22)</time_frame>
        <population>Analysis was performed on the PP set.</population>
        <group_list>
          <group group_id="O1">
            <title>cTIV (Adults)</title>
            <description>Subjects ≥18 to ≤60 years of age who received one vaccination of cell culture-derived influenza virus vaccine (cTIV)</description>
          </group>
          <group group_id="O2">
            <title>TIV (Adults)</title>
            <description>Subjects ≥18 to ≤60 years of age who received one vaccination of egg-derived influenza virus vaccine (TIV)</description>
          </group>
          <group group_id="O3">
            <title>cTIV (Elderly)</title>
            <description>Subjects ≥61 years of age who received one vaccination of cell culture-derived influenza virus vaccine (cTIV)</description>
          </group>
          <group group_id="O4">
            <title>TIV (Elderly)</title>
            <description>Subjects ≥61 years of age who received one vaccination of egg-derived influenza virus vaccine (TIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratio of Subjects After One Vaccination of cTIV or TIV</title>
          <description>Immunogenicity was measured as the geometric mean ratio (GMR), calculated as the ratio of postvaccination to prevaccination HI Geometric Mean Titers (GMTs), three weeks after (day 22) one vaccination of cTIV or TIV. In compliance with the requirements of the EMEA recommendations (CPMP/BWP/2490/00, CPMP/BWP/214/96), this criterion is met if the GMR (day 22/day 1) in HI antibody titer is &gt;2.5 in the ≥18 to ≤60 years of age group or &gt;2.0 in the ≥61 years of age group.</description>
          <population>Analysis was performed on the PP set.</population>
          <units>Ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="650"/>
                <count group_id="O2" value="644"/>
                <count group_id="O3" value="672"/>
                <count group_id="O4" value="674"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="10" upper_limit="13"/>
                    <measurement group_id="O2" value="11" lower_limit="9.34" upper_limit="12"/>
                    <measurement group_id="O3" value="5.74" lower_limit="5.15" upper_limit="6.41"/>
                    <measurement group_id="O4" value="5.96" lower_limit="5.35" upper_limit="6.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.99" lower_limit="5.37" upper_limit="6.68"/>
                    <measurement group_id="O2" value="7.08" lower_limit="6.34" upper_limit="7.9"/>
                    <measurement group_id="O3" value="7.25" lower_limit="6.47" upper_limit="8.12"/>
                    <measurement group_id="O4" value="8.36" lower_limit="7.46" upper_limit="9.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="12" upper_limit="15"/>
                    <measurement group_id="O2" value="12" lower_limit="11" upper_limit="13"/>
                    <measurement group_id="O3" value="12" lower_limit="11" upper_limit="13"/>
                    <measurement group_id="O4" value="9.29" lower_limit="8.42" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority testing in immune response (GMR) after one vaccination of cTIV to that of TIV vaccine for strain A/H1N1 in adults.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The value of GMR ratio of cTIV to TIV is &gt;0.5 (i.e., the GMR of the cTIV group is non-inferior to that of the TIV group if, for strain A/H1N1, the lower limit of the 95% CI for ratio of GMRs at day 22 is greater than 0.5).</non_inferiority_desc>
            <param_type>Ratio of GMRs</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority testing in immune response (GMR) after one vaccination of cTIV to that of TIV vaccine for strain A/H3N2 in adults.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The value of GMR ratio of cTIV to TIV is &gt;0.5 (i.e., the GMR of the cTIV group is non-inferior to that of the TIV group if, for strain A/H3N2, the lower limit of the 95% CI for ratio of GMRs at day 22 is greater than 0.5).</non_inferiority_desc>
            <param_type>Ratio of GMRs</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority testing in immune response (GMR) after one vaccination of cTIV to that of TIV vaccine for strain B in adults.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The value of GMR ratio of cTIV to TIV is &gt;0.5 (i.e., the GMR of the cTIV group is non-inferior to that of the TIV group if, for strain B, the lower limit of the 95% CI for ratio of GMRs at day 22 is greater than 0.5).</non_inferiority_desc>
            <param_type>Ratio of GMRs</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority testing in immune response (GMR) after one vaccination of cTIV to that of TIV vaccine for strain A/H1N1 in the elderly population.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The value of GMR ratio of cTIV to TIV is &gt;0.5 (i.e., the GMR of the cTIV group is non-inferior to that of the TIV group if, for strain A/H1N1, the lower limit of the 95% CI for ratio of GMRs at day 22 is greater than 0.5).</non_inferiority_desc>
            <param_type>Ratio of GMRs</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority testing in immune response (GMR) after one vaccination of cTIV to that of TIV vaccine for strain A/H3N2 in the elderly population.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The value of GMR ratio of cTIV to TIV is &gt;0.5 (i.e., the GMR of the cTIV group is non-inferior to that of the TIV group if, for strain A/H3N2, the lower limit of the 95% CI for ratio of GMRs at day 22 is greater than 0.5).</non_inferiority_desc>
            <param_type>Ratio of GMRs</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority testing in immune response (GMR) after one vaccination of cTIV to that of TIV vaccine for strain B in the elderly population.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The value of GMR ratio of cTIV to TIV is &gt;0.5 (i.e., the GMR of the cTIV group is non-inferior to that of the TIV group if, for strain B, the lower limit of the 95% CI for ratio of GMRs at day 22 is greater than 0.5).</non_inferiority_desc>
            <param_type>Ratio of GMRs</param_type>
            <param_value>1.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.11</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Reported Solicited Local and Systemic Reactions up to 7 Days After Vaccination</title>
        <description>The solicited local and systemic reactions were collected from day 1 up to and including day 7 after vaccination for both the vaccine groups.</description>
        <time_frame>Up to 7 days postvaccination</time_frame>
        <population>Analysis was done on Safety population i.e., all subjects with vaccination and with some post-baseline safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>cTIV (Adults)</title>
            <description>Subjects ≥18 to ≤60 years of age who received one vaccination of cell culture-derived influenza virus vaccine (cTIV)</description>
          </group>
          <group group_id="O2">
            <title>TIV (Adults)</title>
            <description>Subjects ≥18 to ≤60 years of age who received one vaccination of egg-derived influenza virus vaccine (TIV)</description>
          </group>
          <group group_id="O3">
            <title>cTIV (Elderly)</title>
            <description>Subjects ≥61 years of age who received one vaccination of cell culture-derived influenza virus vaccine (cTIV)</description>
          </group>
          <group group_id="O4">
            <title>TIV (Elderly)</title>
            <description>Subjects ≥61 years of age who received one vaccination of egg-derived influenza virus vaccine (TIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Reported Solicited Local and Systemic Reactions up to 7 Days After Vaccination</title>
          <description>The solicited local and systemic reactions were collected from day 1 up to and including day 7 after vaccination for both the vaccine groups.</description>
          <population>Analysis was done on Safety population i.e., all subjects with vaccination and with some post-baseline safety data.</population>
          <units>Number of Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="652"/>
                <count group_id="O2" value="648"/>
                <count group_id="O3" value="678"/>
                <count group_id="O4" value="676"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="106"/>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141"/>
                    <measurement group_id="O2" value="111"/>
                    <measurement group_id="O3" value="64"/>
                    <measurement group_id="O4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="70"/>
                    <measurement group_id="O4" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="46"/>
                    <measurement group_id="O4" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="69"/>
                    <measurement group_id="O4" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="44"/>
                    <measurement group_id="O4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="73"/>
                    <measurement group_id="O4" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥38°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stayed home due to reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic/antipyretic medication used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the study (day 1 to day 180)</time_frame>
      <desc>All serious adverse events (AEs) were collected throughout the study (day 1 to day 180).</desc>
      <group_list>
        <group group_id="E1">
          <title>cTIV (Adults)</title>
          <description>Subjects ≥18 to ≤60 years of age who received one vaccination of cell culture-derived influenza virus vaccine (cTIV)</description>
        </group>
        <group group_id="E2">
          <title>TIV (Adults)</title>
          <description>Subjects ≥18 to ≤60 years of age who received one vaccination of egg-derived influenza virus vaccine (TIV)</description>
        </group>
        <group group_id="E3">
          <title>cTIV (Elderly)</title>
          <description>Subjects ≥61 years of age who received one vaccination of cell culture-derived influenza virus vaccine (cTIV)</description>
        </group>
        <group group_id="E4">
          <title>TIV (Elderly)</title>
          <description>Subjects ≥61 years of age who received one vaccination of egg-derived influenza virus vaccine (TIV)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="652"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="648"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="678"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="676"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="648"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="678"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="648"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="678"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="648"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="648"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="648"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="678"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="648"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="676"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="652"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="648"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Inner ear disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="648"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="676"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Angle closure glaucoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="648"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="648"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="676"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="648"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="648"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="648"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="648"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="648"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="648"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="648"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="676"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="648"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="676"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="652"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="648"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="648"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="678"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="676"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="648"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Postoperative hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="648"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Carbon monoxide poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="648"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="648"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="648"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="676"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="648"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="676"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign oesophageal neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="648"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Gallbladder cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="648"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="648"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="648"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="648"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="676"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="648"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="648"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="648"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Syncope Vasovagal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="648"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="676"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="648"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="676"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="648"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="676"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive airways disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="648"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="648"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="676"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Atherosclerosis obliterans</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="648"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="648"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="648"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="676"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="261" subjects_at_risk="652"/>
                <counts group_id="E2" subjects_affected="257" subjects_at_risk="648"/>
                <counts group_id="E3" subjects_affected="224" subjects_at_risk="678"/>
                <counts group_id="E4" subjects_affected="207" subjects_at_risk="676"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="92" subjects_affected="92" subjects_at_risk="652"/>
                <counts group_id="E2" events="106" subjects_affected="106" subjects_at_risk="648"/>
                <counts group_id="E3" events="72" subjects_affected="72" subjects_at_risk="678"/>
                <counts group_id="E4" events="72" subjects_affected="72" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="38" subjects_affected="38" subjects_at_risk="652"/>
                <counts group_id="E2" events="42" subjects_affected="42" subjects_at_risk="648"/>
                <counts group_id="E3" events="37" subjects_affected="37" subjects_at_risk="678"/>
                <counts group_id="E4" events="29" subjects_affected="29" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="141" subjects_affected="141" subjects_at_risk="652"/>
                <counts group_id="E2" events="111" subjects_affected="111" subjects_at_risk="648"/>
                <counts group_id="E3" events="64" subjects_affected="64" subjects_at_risk="678"/>
                <counts group_id="E4" events="32" subjects_affected="32" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="76" subjects_affected="76" subjects_at_risk="652"/>
                <counts group_id="E2" events="75" subjects_affected="75" subjects_at_risk="648"/>
                <counts group_id="E3" events="74" subjects_affected="74" subjects_at_risk="678"/>
                <counts group_id="E4" events="76" subjects_affected="76" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="73" subjects_affected="73" subjects_at_risk="652"/>
                <counts group_id="E2" events="73" subjects_affected="73" subjects_at_risk="648"/>
                <counts group_id="E3" events="74" subjects_affected="74" subjects_at_risk="678"/>
                <counts group_id="E4" events="85" subjects_affected="85" subjects_at_risk="676"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="37" subjects_affected="37" subjects_at_risk="652"/>
                <counts group_id="E2" events="36" subjects_affected="36" subjects_at_risk="648"/>
                <counts group_id="E3" events="48" subjects_affected="48" subjects_at_risk="678"/>
                <counts group_id="E4" events="48" subjects_affected="48" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="46" subjects_affected="46" subjects_at_risk="652"/>
                <counts group_id="E2" events="51" subjects_affected="51" subjects_at_risk="648"/>
                <counts group_id="E3" events="47" subjects_affected="47" subjects_at_risk="678"/>
                <counts group_id="E4" events="58" subjects_affected="58" subjects_at_risk="676"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="87" subjects_affected="87" subjects_at_risk="652"/>
                <counts group_id="E2" events="88" subjects_affected="88" subjects_at_risk="648"/>
                <counts group_id="E3" events="75" subjects_affected="75" subjects_at_risk="678"/>
                <counts group_id="E4" events="75" subjects_affected="75" subjects_at_risk="676"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="648"/>
                <counts group_id="E3" events="45" subjects_affected="45" subjects_at_risk="678"/>
                <counts group_id="E4" events="48" subjects_affected="48" subjects_at_risk="676"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

